Titre A Phase 4 Long-term Follow-up Study to Define the Safety Profile of Radium-223 Dichloride
Protocole ID 16996
ClinicalTrials.gov ID NCT02312960
Type(s) de cancer Autre
Phase Phase IV
Institution CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL  
Ville Montréal
Investigateur(trice) principal(e) Dr Fred Saad
Coordonnateur(trice) Amal Nadiri
514-890-8000 poste 26074
Statut Actif en recrutement
Critètes d'éligibilité
  • Subject was previously enrolled in a selected company sponsored feeder trial, and has received at least 1 dose of radium 223 dichloride or placebo in the feeder trial
Critètes d'exclusion
  • Not applicable to this follow up study